DK0702563T3 - Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme - Google Patents

Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme

Info

Publication number
DK0702563T3
DK0702563T3 DK94918667T DK94918667T DK0702563T3 DK 0702563 T3 DK0702563 T3 DK 0702563T3 DK 94918667 T DK94918667 T DK 94918667T DK 94918667 T DK94918667 T DK 94918667T DK 0702563 T3 DK0702563 T3 DK 0702563T3
Authority
DK
Denmark
Prior art keywords
growth factor
present
compositions
antibodies specific
immunogenic
Prior art date
Application number
DK94918667T
Other languages
English (en)
Inventor
Carol A Nacy
John W Holaday
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc filed Critical Entremed Inc
Application granted granted Critical
Publication of DK0702563T3 publication Critical patent/DK0702563T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
DK94918667T 1993-05-27 1994-05-26 Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme DK0702563T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6871793A 1993-05-27 1993-05-27
PCT/US1994/005927 WO1994027635A1 (en) 1993-05-27 1994-05-26 Compositions and methods for treating cancer and hyperproliferative disorders

Publications (1)

Publication Number Publication Date
DK0702563T3 true DK0702563T3 (da) 2003-11-10

Family

ID=22084279

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94918667T DK0702563T3 (da) 1993-05-27 1994-05-26 Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme

Country Status (10)

Country Link
US (1) US5919459A (da)
EP (1) EP0702563B1 (da)
JP (2) JPH08510751A (da)
AT (1) ATE246513T1 (da)
AU (1) AU6989094A (da)
CA (1) CA2163652A1 (da)
DE (1) DE69433013T2 (da)
DK (1) DK0702563T3 (da)
ES (1) ES2204919T3 (da)
WO (1) WO1994027635A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248799A1 (en) * 1993-05-27 2004-12-09 Holaday John W. Compositions and methods for treating cancer and hyperproliferative disorders
US6805865B1 (en) * 1993-05-27 2004-10-19 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6908910B2 (en) * 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
IL143580A0 (en) 1998-12-11 2002-04-21 Pharmasolutions Inc Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof
WO2000053219A2 (en) * 1999-03-11 2000-09-14 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US20060009393A1 (en) * 1999-10-02 2006-01-12 The Government of the U.S.A as represented by the Secretary of the Dept. of Health & Human Services Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)
US20020012651A1 (en) * 2000-05-10 2002-01-31 Loeb Marvin P. Release of therapeutic agents in a vessel or tissue
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
WO2002100345A2 (en) * 2001-06-11 2002-12-19 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods of using the same
CA2454920C (en) * 2001-07-26 2013-06-25 Otago Innovation Limited Antigenic compositions
WO2004002418A2 (en) * 2002-06-26 2004-01-08 Entremed, Inc Compositions and methods comprising protein activated receptor antagonists
JP2006517917A (ja) * 2002-12-19 2006-08-03 アルザ・コーポレーシヨン 血管新生性の組織増殖の治療方法
CA2527074A1 (en) * 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
DE10333509B4 (de) * 2003-07-18 2007-05-03 Technische Universität Dresden Gegen VEGF gerichtete Erkennungsmoleküle und die Verwendung dieser
WO2005089256A2 (en) * 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
JP2008510726A (ja) * 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
WO2006058298A2 (en) * 2004-11-29 2006-06-01 Entremed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
CA2604683C (en) * 2005-04-12 2019-04-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
AU2007227256B2 (en) * 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
US20080226707A1 (en) * 2007-03-05 2008-09-18 Jill Helms WNT compositions and methods of use thereof
JP2010523676A (ja) * 2007-04-13 2010-07-15 デューク ユニバーシティ ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
WO2010114628A2 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2011140296A1 (en) * 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4879236A (en) * 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5194384A (en) * 1987-04-23 1993-03-16 Bystryn Jean Claude Method for preparing human meloma vaccine
US4895835A (en) * 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
EP0440742B1 (en) * 1988-10-27 1997-01-15 The Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
AU4633893A (en) * 1992-06-17 1994-01-04 University Of Massachusetts Medical Center Liposomal formulations for administering to cancer patients
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein

Also Published As

Publication number Publication date
ES2204919T3 (es) 2004-05-01
WO1994027635A1 (en) 1994-12-08
EP0702563B1 (en) 2003-08-06
US5919459A (en) 1999-07-06
DE69433013D1 (de) 2003-09-11
DE69433013T2 (de) 2004-06-03
ATE246513T1 (de) 2003-08-15
JPH08510751A (ja) 1996-11-12
EP0702563A1 (en) 1996-03-27
JP2007262102A (ja) 2007-10-11
EP0702563A4 (en) 1997-10-01
AU6989094A (en) 1994-12-20
CA2163652A1 (en) 1994-12-08

Similar Documents

Publication Publication Date Title
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
AU6642390A (en) Methods and compositions for promoting immunopotentiation
AU2308595A (en) Monoclonal antibodies against hiv-1 and vaccines made thereo f
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
CA2284079A1 (en) Immunotoxins and methods of inducing immune tolerance
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
UA41381C2 (uk) Спосіб вакцинації птиці in ovo проти кокцидіозу
DE69434244D1 (de) Verbesserte krebstherapie
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE460179T1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
EP0684831A4 (en) ALLOGENIC VACCINE AND METHOD FOR SYNTHESIZING THE SAME.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69232140D1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
NO20012214L (no) Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller
DE4411425A1 (de) Verfahren zur Herstellung einer Tumorvakzine für die Aktive Spezifische Immuntherapie (ASI)
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.